Navigation Links
FDA Approves Expanded Labeling for Campath(R) to Include First-line Treatment for Leading Form of Adult Leukemia
Date:9/22/2007

Study Data Demonstrated Improved Progression-free Survival with Campath

CAMBRIDGE, Mass. and WAYNE, N.J., Sept. 20 /PRNewswire-FirstCall/ -- Genzyme Corp. (Nasdaq: GENZ) and Bayer HealthCare Pharmaceuticals Inc. (NYSE: BAY) today announced that the U.S. Food and Drug Administration (FDA) has approved a supplemental biologics license application (sBLA) for Campath(R) (alemtuzumab) and granted regular approval for single-agent Campath for the treatment of B-cell chronic lymphocytic leukemia (B-CLL). Campath was initially approved in 2001 under accelerated approval regulations and the FDA has determined that the study results submitted in the sBLA fulfill the post- marketing commitment to verify clinical benefit. A label expansion is under consideration in Europe.

"Campath is clearly an important single agent for the first-line treatment of CLL," said Peter Hillmen, MB, ChB, of the Leeds General Infirmary, Leeds, United Kingdom, and the lead investigator of the pivotal study comparing Campath against chlorambucil. "We are excited to be entering an era where our improved understanding of CLL, coupled with more advanced laboratory tests and targeted therapy options like Campath, have dramatically changed the first- line treatment approach for this type of leukemia."

Campath works in an entirely different way than chemotherapy, and is the first and only monoclonal antibody approved by the FDA for the treatment of B- CLL.

"The data that supported this label expa
'/>"/>

SOURCE Genzyme Corp. and Bayer HealthCare Pharmaceuticals Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine news :

1. FDA approves Phase 0 trial which tests experimental drugs on humans
2. FDA Approves Contraceptive Ring
3. FDA approves new device to treat womens bleeding disorder
4. FDA Approves New HIV Drug, Viread
5. FDA Approves Birth Control Skin Patch
6. FDA approves surgical gel
7. FDA Approves New Arthritis Drug, Bextra
8. FDA Approves Elidel Cream for Eczema
9. FDA approves drug for rare liver disease
10. FDA approves first pocket-sized EKG machine
11. FDA Approves New Anti-Clotting Drug
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/12/2008)...Newswire-USNewswire/ -- Michael A.,Sandler, MD, a ...led as,president of the 15,000 member Michigan Sta...meeting of the MSMS House of Delegates on May 3 in...rsity School of Medicine, Doctor,Sandler is senior...t Henry,Ford Hospital and currently serves on the ...
(Date:5/12/2008)...RNewswire-FirstCall/ -- China Yingxia,Internationa..." or "the,Company"), a leading provider in the nut...nufacture and distribution of organic nutritional ...ucts in the People,s Republic,of China ("PRC"), an...riday, May 16, 2008, at 10:00 a.m. EDT, to discuss...
(Date:5/12/2008)...cians from Chongqing Bureau of Health, BLOOMING...thPartners,Institute for Medical Education is host...physicians ever to visit Minnesota. During their,t...tal- and clinic-based,patient care, learn about he...clinical research methodology., "We,re honored ...
(Date:5/12/2008)...ire/ -- Fairbank Farms, a national,ground beef pro...round beef,products produced at its Ashville, N.Y.... BJ,s, and Wilson Farms retail outlets and C&S Who...tain small pieces of hard plastic. All,recalled pr...5/15/08, or a,"Julian date 124" on the package,s l...
Breaking Medicine News(10 mins):Health News:Michael A. Sandler, MD, Installed as President of Michigan State Medical Society 2Health News:China Yingxia International, Inc. Announces Conference Call to Discuss First Quarter 2008 Results 2Health News:First Major Chinese Medical Delegation Visits Minnesota 2Health News:Fairbank Farms Issues Voluntary Recall for Selected Ground Beef Products 2
...tudies have shown that salt intake is directly lin...s estimated that up to 150,000 Americans die// eac...lt. A recent study suggests salt intake and asth...eborough and Fogarty, two researchers observe that...
...h conducted by Dr. Martijn B.A. van Doorn of the C...rlands on 90 obese people revealed that garlic has...l level or allied heart ailments. The finding, wh...nal of Clinical Nutrition puts forth a theory whic...
... Lewis Rothberg of the University of Rochester was...a recent discovery by one of his team members//. ...rkable research. They developed cost effective met... This will ensure better health and clean drinking...
...: A 14 year old teenage boy is confirmed to be sev... and is presently undergoing treatment//, an Indon...first human case of bird flu in 2007; with this, t...n the region is 75, out of which 57 did not surviv...
Other Medicine News:Health News:Quick and Inexpensive DNA Testing 2
(Date:5/12/2008)...A, May 12 /- GeoVax Labs, I...HIV/AIDS vaccine development,company, announced to...stock purchase agreement with Fusion Capital Fund ... The Company may sell up to $10 million of its com... a 25-month period after the Securities and,Exchan...
(Date:5/12/2008)...es the Optimal Combination of Scaffolding, Deliver...lity, TEL AVIV, Israel, May 12 /- Me... Mark for its Presillion(TM) CoCr Coronary Stent,...ns with a technologically,innovative flexible clos...he superb scaffolding the unprecedented,balance of...
(Date:5/12/2008)...ELPHIA, May 12 /PRNewswire-USNewswire/ -- GlaxoSmi...ternational Group (BIG), a leading,academic breast...oups, the,Spanish Breast Cancer Cooperative Group ...se III study that will examine the role of TYKERB(...TTO (Neoadjuvant Lapatinib and/or,Trastuzumab Trea...
(Date:5/9/2008)...Fla., May 9 /PRNewswire-USNewswire/ -- Osteoarthri...ition that affects almost 50,million people in the...artilage in bone joints. The novel investigational...al analgesic, provided significant relief,for pati...eated with,placebo, and with fewer gastrointestina...
Breaking Medicine Technology:GeoVax Secures $10 Million Financing Commitment 2GeoVax Secures $10 Million Financing Commitment 3Medinol Receives CE Mark for Presillion(TM) Cobalt Chromium Coronary Stent on Rx System, an Advanced Evolution of the NIR(R) Family of Stents 2TYKERB(R) (Lapatinib) to be Investigated in Landmark Early Breast Cancer Trial 2TYKERB(R) (Lapatinib) to be Investigated in Landmark Early Breast Cancer Trial 3TYKERB(R) (Lapatinib) to be Investigated in Landmark Early Breast Cancer Trial 4TYKERB(R) (Lapatinib) to be Investigated in Landmark Early Breast Cancer Trial 5TYKERB(R) (Lapatinib) to be Investigated in Landmark Early Breast Cancer Trial 6TYKERB(R) (Lapatinib) to be Investigated in Landmark Early Breast Cancer Trial 7Results of Phase 3 Study Show Tapentadol IR Relieves Acute Pain and Offers Favorable Gastrointestinal Tolerability Profile 2Results of Phase 3 Study Show Tapentadol IR Relieves Acute Pain and Offers Favorable Gastrointestinal Tolerability Profile 3Results of Phase 3 Study Show Tapentadol IR Relieves Acute Pain and Offers Favorable Gastrointestinal Tolerability Profile 4Results of Phase 3 Study Show Tapentadol IR Relieves Acute Pain and Offers Favorable Gastrointestinal Tolerability Profile 5Mayor Bloomberg Declares March 6 2008 World Glaucoma Day in New York City 12887 1Mayor Bloomberg Declares March 6 2008 World Glaucoma Day in New York City 12887 2Medication Management Systems Names New President and COO 12883 1Medication Management Systems Names New President and COO 12883 2Alzheimers Foundation of America Awards Grants to Local Groups Nationwide 12878 1Alzheimers Foundation of America Awards Grants to Local Groups Nationwide 12878 2Bacteria beware 3A MIT student invents knock out punch for antibiotic resistance 12875 1Bacteria beware 3A MIT student invents knock out punch for antibiotic resistance 12875 2Bacteria beware 3A MIT student invents knock out punch for antibiotic resistance 12875 3Bacteria beware 3A MIT student invents knock out punch for antibiotic resistance 12875 4
...NGLE PARK, N.C. & SHERBROOKE, Quebec--(BUSINES... biopharmaceutical,company developing small molecu... metabolic diseases, today announced positive,resu...elerating,gastric emptying in diabetic patients wi...study were presented at the American,Diabetes Asso...
...INESS WIRE)--Jun 25, 2007 - New data from an,inves... Association,(ADA) 67th Annual Scientific Sessions...via(TM) (sitagliptin) and metformin,demonstrated s...ction in patients with type 2 diabetes. Pancreatic...f the body to produce,insulin, a hormone which pla...
Other Medicine Technology:Tranzyme Pharma Presents Initial Phase IIa Data for its Novel,Ghrelin Agonist, TZP-101, in Patients with Diabetic Gastroparesis 2Tranzyme Pharma Presents Initial Phase IIa Data for its Novel,Ghrelin Agonist, TZP-101, in Patients with Diabetic Gastroparesis 3An Investigational Study Released at ADA Showed that Initial,Combination Therapy with Januvia (sitagliptin) and Metformin Led to,Improvement in Markers of Beta Cell Function in Patients with Type,2 Diabetes 2An Investigational Study Released at ADA Showed that Initial,Combination Therapy with Januvia (sitagliptin) and Metformin Led to,Improvement in Markers of Beta Cell Function in Patients with Type,2 Diabetes 3An Investigational Study Released at ADA Showed that Initial,Combination Therapy with Januvia (sitagliptin) and Metformin Led to,Improvement in Markers of Beta Cell Function in Patients with Type,2 Diabetes 4An Investigational Study Released at ADA Showed that Initial,Combination Therapy with Januvia (sitagliptin) and Metformin Led to,Improvement in Markers of Beta Cell Function in Patients with Type,2 Diabetes 5An Investigational Study Released at ADA Showed that Initial,Combination Therapy with Januvia (sitagliptin) and Metformin Led to,Improvement in Markers of Beta Cell Function in Patients with Type,2 Diabetes 6An Investigational Study Released at ADA Showed that Initial,Combination Therapy with Januvia (sitagliptin) and Metformin Led to,Improvement in Markers of Beta Cell Function in Patients with Type,2 Diabetes 7An Investigational Study Released at ADA Showed that Initial,Combination Therapy with Januvia (sitagliptin) and Metformin Led to,Improvement in Markers of Beta Cell Function in Patients with Type,2 Diabetes 8An Investigational Study Released at ADA Showed that Initial,Combination Therapy with Januvia (sitagliptin) and Metformin Led to,Improvement in Markers of Beta Cell Function in Patients with Type,2 Diabetes 9An Investigational Study Released at ADA Showed that Initial,Combination Therapy with Januvia (sitagliptin) and Metformin Led to,Improvement in Markers of Beta Cell Function in Patients with Type,2 Diabetes 10An Investigational Study Released at ADA Showed that Initial,Combination Therapy with Januvia (sitagliptin) and Metformin Led to,Improvement in Markers of Beta Cell Function in Patients with Type,2 Diabetes 11An Investigational Study Released at ADA Showed that Initial,Combination Therapy with Januvia (sitagliptin) and Metformin Led to,Improvement in Markers of Beta Cell Function in Patients with Type,2 Diabetes 12An Investigational Study Released at ADA Showed that Initial,Combination Therapy with Januvia (sitagliptin) and Metformin Led to,Improvement in Markers of Beta Cell Function in Patients with Type,2 Diabetes 13An Investigational Study Released at ADA Showed that Initial,Combination Therapy with Januvia (sitagliptin) and Metformin Led to,Improvement in Markers of Beta Cell Function in Patients with Type,2 Diabetes 14An Investigational Study Released at ADA Showed that Initial,Combination Therapy with Januvia (sitagliptin) and Metformin Led to,Improvement in Markers of Beta Cell Function in Patients with Type,2 Diabetes 15An Investigational Study Released at ADA Showed that Initial,Combination Therapy with Januvia (sitagliptin) and Metformin Led to,Improvement in Markers of Beta Cell Function in Patients with Type,2 Diabetes 16An Investigational Study Released at ADA Showed that Initial,Combination Therapy with Januvia (sitagliptin) and Metformin Led to,Improvement in Markers of Beta Cell Function in Patients with Type,2 Diabetes 17An Investigational Study Released at ADA Showed that Initial,Combination Therapy with Januvia (sitagliptin) and Metformin Led to,Improvement in Markers of Beta Cell Function in Patients with Type,2 Diabetes 18An Investigational Study Released at ADA Showed that Initial,Combination Therapy with Januvia (sitagliptin) and Metformin Led to,Improvement in Markers of Beta Cell Function in Patients with Type,2 Diabetes 19An Investigational Study Released at ADA Showed that Initial,Combination Therapy with Januvia (sitagliptin) and Metformin Led to,Improvement in Markers of Beta Cell Function in Patients with Type,2 Diabetes 20An Investigational Study Released at ADA Showed that Initial,Combination Therapy with Januvia (sitagliptin) and Metformin Led to,Improvement in Markers of Beta Cell Function in Patients with Type,2 Diabetes 21An Investigational Study Released at ADA Showed that Initial,Combination Therapy with Januvia (sitagliptin) and Metformin Led to,Improvement in Markers of Beta Cell Function in Patients with Type,2 Diabetes 22An Investigational Study Released at ADA Showed that Initial,Combination Therapy with Januvia (sitagliptin) and Metformin Led to,Improvement in Markers of Beta Cell Function in Patients with Type,2 Diabetes 23An Investigational Study Released at ADA Showed that Initial,Combination Therapy with Januvia (sitagliptin) and Metformin Led to,Improvement in Markers of Beta Cell Function in Patients with Type,2 Diabetes 24An Investigational Study Released at ADA Showed that Initial,Combination Therapy with Januvia (sitagliptin) and Metformin Led to,Improvement in Markers of Beta Cell Function in Patients with Type,2 Diabetes 25An Investigational Study Released at ADA Showed that Initial,Combination Therapy with Januvia (sitagliptin) and Metformin Led to,Improvement in Markers of Beta Cell Function in Patients with Type,2 Diabetes 26An Investigational Study Released at ADA Showed that Initial,Combination Therapy with Januvia (sitagliptin) and Metformin Led to,Improvement in Markers of Beta Cell Function in Patients with Type,2 Diabetes 27An Investigational Study Released at ADA Showed that Initial,Combination Therapy with Januvia (sitagliptin) and Metformin Led to,Improvement in Markers of Beta Cell Function in Patients with Type,2 Diabetes 28An Investigational Study Released at ADA Showed that Initial,Combination Therapy with Januvia (sitagliptin) and Metformin Led to,Improvement in Markers of Beta Cell Function in Patients with Type,2 Diabetes 29An Investigational Study Released at ADA Showed that Initial,Combination Therapy with Januvia (sitagliptin) and Metformin Led to,Improvement in Markers of Beta Cell Function in Patients with Type,2 Diabetes 30An Investigational Study Released at ADA Showed that Initial,Combination Therapy with Januvia (sitagliptin) and Metformin Led to,Improvement in Markers of Beta Cell Function in Patients with Type,2 Diabetes 31An Investigational Study Released at ADA Showed that Initial,Combination Therapy with Januvia (sitagliptin) and Metformin Led to,Improvement in Markers of Beta Cell Function in Patients with Type,2 Diabetes 32
...laboratory and a worldwide leader in innovative la...extensive test menu of highly complex and unique m...wned by the University of Utah, ARUP Laboratories'...iversity teaching hospitals and children's hospita...
...laboratory and a worldwide leader in innovative la...extensive test menu of highly complex and unique m...wned by the University of Utah, ARUP Laboratories'...iversity teaching hospitals and children's hospita...
...laboratory and a worldwide leader in innovative la...extensive test menu of highly complex and unique m...wned by the University of Utah, ARUP Laboratories'...iversity teaching hospitals and children's hospita...
...laboratory and a worldwide leader in innovative la...extensive test menu of highly complex and unique m...wned by the University of Utah, ARUP Laboratories'...iversity teaching hospitals and children's hospita...
Medicine Products: